COMMUNIQUÉS West-GlobeNewswire

Samumed Announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in Knee Osteoarthritis
28/02/2019
STRIDES Phase 3 studies to commence first half of 2019 SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug [...]
OncBioMune Announces Consulting Agreement with CATO Research LLC for Developing PGT, a Protein Drug Complex Targeting CD71 for Refractory Cancers
28/02/2019
BATON ROUGE, La., Feb. 28, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary [...]
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019
28/02/2019
CORAL GABLES, Fla., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with [...]
Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference
28/02/2019
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the [...]
Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
28/02/2019
AUSTIN, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare [...]
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019
28/02/2019
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, [...]
UAHC Subsidiary American Sustainable Rubber Company, LLC Appoints Leading Plant Researcher Dr. Katrina Cornish as Scientific Advisor
28/02/2019
CHICAGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- United American Healthcare Corporation (OTC: UAHC), an emerging technology holding company, today announced the appointment of Dr. Katrina Cornish as scientific advisor of its [...]
Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting
28/02/2019
HOUSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of [...]
Genocea Reports Fourth Quarter 2018 Results and Announces Hiring of New Chief Financial Officer
28/02/2019
Company advancing lead clinical-stage neoantigen cancer vaccine candidate and expanding pipeline into adoptive cell therapy Diantha Duvall to join as CFO, bringing broad life science financial leadership experience [...]
GeneDx Joins Rare Disease Organizations to Support Rare Disease Day 2019
28/02/2019
Employees Nationwide Participate in Rare Disease Day Virtual Race Campaign GAITHERSBURG, Md., Feb. 28, 2019 (GLOBE NEWSWIRE) -- GeneDx, Inc., a subsidiary of OPKO Health, Inc.’s BioReference Laboratories, Inc. and [...]
Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019
28/02/2019
BERKELEY, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that three abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2019, [...]
Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
28/02/2019
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and others worldwide [...]
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
28/02/2019
Shareholders approve 22 nd consecutive dividend increase to CHF 2.85 (+2%) per share for 2018; representing a 3.1% yield and approximately 57% payout of free cash flow Overwhelming majority of shareholders approve [...]
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale
28/02/2019
Les actionnaires approuvent la 22 e hausse consécutive du dividende à CHF 2.85 (+2%) par action pour 2018, soit un rendement de 3,1% et une distribution du free cash-flow d'environ 57% Une majorité écrasante d' [...]
Olainfarm invites to Fourth Quarter 2018 Investor Conference Webinar
28/02/2019
AS Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on March 5, 2019 at 16:00 (EET). To join the webinar please follow the [...]
Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
28/02/2019
HAMILTON, Bermuda, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Cowen and Company 39 th Annual Healthcare Conference on Wednesday, March 13 [...]
Cytokinetics Joins Global Initiative To Recognize International Rare Disease Day
28/02/2019
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is standing with the European Organisation for Rare Diseases (EURORDIS) and the National [...]
Radient Technologies Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update
28/02/2019
EDMONTON, Alberta, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI; OTCQX: RDDTF ) has released its financial results for the third fiscal quarter ended [...]
Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy
28/02/2019
SPINRAZA is the standard of care for treating infants, children and adults with spinal muscular atrophy, a rare, genetic neuromuscular disease SPINRAZA was approved under the China National Medical Products Association [...]

Pages